Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HAO472
- Development stage
- Phase 1
- Lead developer
- Jiangsu HengRui Medicine Co., Ltd.
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HAO472 is an orally bioavailable small molecule inhibitor of the Menin-KMT2A (Mixed Lineage Leukemia 1 or MLL1) protein-protein interaction, developed by Jiangsu Hengrui Medicine. It is specifically designed to treat patients with relapsed or refractory acute myeloid leukemia (AML), particularly those with KMT2A rearrangements or NPM1 mutations. By binding to Menin, HAO472 prevents its association with KMT2A fusion proteins, thereby disrupting the transcriptional complex responsible for maintaining the leukemic phenotype and promoting the differentiation of myeloid blasts. The drug is currently being evaluated in early-phase clinical trials to determine its safety, tolerability, and preliminary efficacy in genetically defined subsets of leukemia.
02
Targets
MEN1 (Menin)
Beyond the preview
Go deeper on HAO472.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HAO472.